Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders

GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

August 7, 2018
GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference

August 3, 2018
GBT Announces New Employment Inducement Grants

August 2, 2018
GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results

Read More News

Associated Team Members

Kevin Starr

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.

Glenn Pierce, M.D., Ph.D.